The University of Edinburgh
Modulation of neuropeptide growth factor signalling by anti-cancer substance-P analogues
Abstract
dc:description.abstractWidespread metastases are characteristic of the most aggressive form of lung cancer, small cell lung cancer (SCLC). Although initially sensitive to treatment by radio- and chemotherapy, SCLC develops chemoresistance so the 2-year survival rate remains less than 5%. The aberrant proliferation of SCLC is sustained by multiple autocrine and paracrine growth loops involving calcium mobilising neuropeptides such as vasopressin (AVP) and gastrin releasing peptide (GRP). The expression of these neuropeptides and their receptors are a hallmark of the disease and present an important target for therapeutic intervention. Analogues of substance-P, including [D-ArgI,D-Phe5,D-Trp7-9,Leu11]-substance-P (SP-D) and [Arg6,D-Trp7-9,NmePhe8]-substance-P (6-11) (SP-G), are novel anti-cancer agents which inhibit the growth of SCLC cells. Investigations into the mechanism of action of substance- P analogues on bombesin receptors revealed that in addition to blocking bombesin-induced mitogenesis and signal transduction they also have agonist activity. This unique pharmacological activity of 'biased agonism' may be centred to the growth inhibitory effects of these agents.
Degree
thesis:*- Grantor dc:publisher
- The University of Edinburgh
- Year dc:date.issued
- 2006
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Tufail-Hanif, Uzma
Identifiers
dc:identifier.*- Handle dc:identifier.uri
- http://hdl.handle.net/1842/30862